Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, G., Thompson, M., Collins, M., Herschtal, A., Hofman, M. S., Johnston, V., Eu, P., Michael, M., Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159597/
https://www.ncbi.nlm.nih.gov/pubmed/24844348
http://dx.doi.org/10.1007/s00259-014-2788-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159597/
https://www.ncbi.nlm.nih.gov/pubmed/24844348
http://dx.doi.org/10.1007/s00259-014-2788-5

Ejemplares similares